GCOS 2021 - Virtual

Dr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the University of Minnesota. She is the section head of Medical Oncology within this division and is Director of Cancer Survivorship Services and Translational Research within the Masonic Cancer Center. She is an active medical oncologist with a special interest in the late effects of cancer therapy, particularly in the area of cardio-oncology. Her research focuses on designing and implementing strategies to help prevent the long term complications of treatments in our cancer survivors, particularly in the areas of cardiovascular health. She is the Chair for the American Society of Clinical Oncology’s Cancer Survivorship Committee, a member of the Executive Board for the Global Cardiooncology Society, associate editor for JACC Cardio-oncology, section editor for Hem/Onc Today on Survivorship and an active member of the ALLIANCE for Cancer Clinical Trials.

Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.

Dr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology at the Perelman School of Medicine at the University of Pennsylvania and serves as the medical director of the Penn Medicine Cardio-Oncology program. He earned his B.S at Yale University and his MD degree at the Johns Hopkins University School of Medicine. Dr. Fradley completed his residency in internal medicine through the Osler Medical Residency Program at the Johns Hopkins Hospital. He then went on to complete fellowships in both cardiology and electrophysiology at Massachusetts General Hospital. As a trained electrophysioloigst, Dr. Fradley has particular interest in the diagnosis and management of arrhythmic complications associated with traditional and novel cancer therapies. He is a member of the American College of Cardiology Electrophysiology Leadership Council and the IC-OS Board of Directors.

Dr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed her residency training in Internal Medicine and Medical Oncology at the Ottawa Hospital, University of Ottawa, Ontario, Canada. She subsequently completed a post graduate research fellowship in clinical trials at the Canadian Cancer Trials Group (CCTG) in Kingston, Ontario, and was appointed as a staff medical oncologist at the Northwestern Ontario Cancer Center in Thunder Bay, Ontario. In 2001, Dr. Dent returned to Ottawa, where she specialized in the treatment of breast cancer. In 2008, Dr. Dent, working with her cardiology colleagues, established a multidisciplinary cardio-oncology clinic in Ottawa; the first of its kind in Canada. In 2011, she founded the Canadian Cardiac Oncology Network (CONN), a not-for-profit organization devoted to optimization of cancer care for patients without compromising cardiovascular health. In 2015, Dr. Dent launched the Global Cardio-Oncology Summit (GCOS), an annual meeting which now attracts oncologists, cardiologists, and allied health care providers from more than 23 countries. Dr. Dent is recognized as a global leader in cardio-oncology. She has travelled extensively around the world sharing her knowledge and expertise on the potential impact of cancer treatment on cardiovascular health. She has published extensively in the area and has co-authored a number of position statements and clinical practice guidelines. Dr. Dent currently serves as an Executive Officer of the International Cardio-Oncology society (ICOS), an organization dedicated to bringing cardiologists, oncologists, and allied health care providers together, to improve the clinical care of patients and save lives. In September 2018, Dr. Dent accepted a staff position in medical oncology at Duke University, where she will continue her efforts in promoting clinical care, education and research in cardio-oncology.

Ms. Blanco was born in New Orleans, LA to Colombian parents and is fully bilingual and bicultural. She received her undergraduate degree at Louisiana State University (LSU) and is a graduate of Thunderbird – the American Graduate School of International Management. She began her career in Research and has accumulated a wealth of knowledge regarding the importance of consumer insights and their implications for marketing and advertising. Ms. Blanco considers herself more an Account Planner than simply an Account Manager or Research Manager. Currently she works as a consultant on a freelance basis. Ms. Blanco is President of Sofia's Hope, which she founded in honor of her eldest daughter, Sofia. She is dedicated to the foundation and making a difference in the world of pediatric cancer. However, Ms. Blanco has always considered her most important role to be that of the mother to both her girls. She lives in South Florida with her husband, Carlos, and daughter, Gabriela.

Anecita Fadol, PhD, FNP-BC, FAANP, FAAN is an Associate Professor and Education Director, Nursing Cardio-Oncology Program at The University of Texas MD Anderson Cancer Center. Dr. Fadol is a nursing pioneer in the evolving field of cardio-oncology. Her extensive and unique expertise in cardio-oncology have been recognized nationally and internationally. She has written numerous book chapters, published in peer-reviewed journals, and is the editor of the “Cardiac Complications of Cancer Therapy”, the first clinical reference book for nurses that examines the complexity of cardiac problems in conjunction with a cancer diagnosis. Her program of research included the validation of the MD Anderson Symptom Inventory-Heart Failure (MDASI-HF) instrument, which was subsequently translated to Chinese and Spanish. She is on the leadership council for the Cardio-Oncology section of the American College of Cardiology. Dr. Fadol is a fellow of the American Academy of Nurse Practitioners, American Academy of Nursing, and was recently awarded as Honorary Fellow of 2021 by the Hong Kong Academy of Nursing.

Christine Brezden-Masley, MD PhD FRCPC is a practicing Medical Oncologist and the Director of the Marvelle Koffler Breast Centre at Mount Sinai Hospital as well as the Medical Director of Cancer Program for Sinai Health in Toronto, Canada. She obtained her PhD in Medical Biophysics at the Princess Margaret Hospital in Toronto and her Medical Degree from the University of Toronto. She is currently an Associate Professor at the University of Toronto and senior scientist for the same Clinical Research Group at the Lunenfeld-Tanenbaum Research Institute for Sinai Health System in Toronto, Canada. Dr Brezden-Masley is the founder of the COMET (Community Oncologists of Metropolitan Toronto) Clinical Trials Consortium, a web-based virtual network promoting cancer clinical trials throughout the Toronto region. She treats both breast and gastrointestinal (colorectal and gastric cancers) malignancies, which are her major areas of research interest. Her main area of clinical research is cardiotoxicity from cancer therapy and is currently the President of the Canadian Cardio-Oncology Network. She is also on the Board of Directors of ReThink Breast Cancer, a national advocacy and support network for young women with breast cancer and My Gut Feeling, a stomach cancer support network for patients, survivors, and caregivers.

Dr. Moore is originally from eastern North Carolina. She completed her undergraduate degree in biology at North Carolina State University and received her doctorate of pharmacy at the UNC Eshelman School of Pharmacy in Chapel Hill. She completed her general residency training at the Durham Veterans Affairs Hospital where she realized her passion for oncology and then continued on to complete oncology residency training at VCU hospital in Richmond, Virginia. After residency, she decided to return home to North Carolina and accepted a position in the breast oncology clinic at the Duke Cancer Institute. She has developed a specific interest in cardio oncology given the cardiotoxicity seen with many breast cancer therapies which led to involvement within the cardio oncology program at Duke. In her free time, she enjoys reading, playing tennis, supporting NC State athletics and spending time with her dog, Chauncey.

Dr Scott Adams is an Assistant Scientist (Toronto General Hospital Research Institute, University Health Network [UHN]) and the Exercise Lead (Ted Rogers Cardiotoxicity Prevention Program, UHN). He is the Director of the ‘Research in Exercise & Cardiorespiratory Health in Oncology’ laboratory (UHN) and a member of the Adolescent and Young Adult Oncology Program (Princess Margaret Cancer Centre) and the Cardiovascular Prevention and Rehabilitation Program (Toronto Rehab Institute). He completed his PhD at the University of Alberta and two post-doctoral fellowships at Memorial Sloan Kettering Cancer Center and the University of Toronto. His research adopts precision medicine and knowledge translation approaches to (1) phenotype cancer patients and survivors using complementary cardiovascular profiling tools (e.g. cardiopulmonary exercise testing, vascular imaging, autonomic function assessments) to augment cardiovascular risk screening and stratification, (2) develop targeted exercise-based multi-modal therapies that target the discrete mechanisms of risk and injury within these phenotype-defined groups, and (3) facilitate the translation of this and related research into practice.

Suzanne McGettigan, MSN, CRNP, ANP-BC, AOCN is an Oncology Nurse Practitioner and Clinical Manager of Advanced Practice Providers and Nursing, at the Abramson Cancer Center at the University of Pennsylvania, in the Division of Hematology-Oncology. She has been a part of the Melanoma and Cutaneous Malignancies Program since 2005 as well as other disease based specialties within the Division. She also is a Clinical Associate at the University of Pennsylvania, School of Nursing, in the graduate Nurse Practitioner program. Through her clinical work, Ms. McGettigan has provided care to patients receiving immunotherapy, targeted therapy, and chemotherapy as well as symptom management and survivorship care to cancer patients. She has been a sub-investigator on a number of therapeutic clinical trials. She has published articles in peer reviewed journals detailing nursing and APP care of patients and provided lectures nationally on these topics. After graduating from Washington and Lee University with a Bachelor of Science in Biology, Ms. McGettigan earned both her Bachelor of Science and Master of Science in Nursing from the University of Pennsylvania. Ms. McGettigan holds certification as an Advanced Oncology Nurse and an Adult Nurse Practitioner. She is an active member of the Oncology Nursing Society, the Advanced Practitioner Society for Hematology Oncology, and the Society of Immunotherapy for Cancer.

Dr. Tochukwu Okwuosa is a cardiologist, Associate Professor of Internal Medicine and the Director of Cardio-Oncology Services at Rush University Medical Center (RUMC). Dr. Okwuosa’s research focuses on identification and prevention of cancer therapy-induced cardiotoxicity. She has received the Cohn’s research award to study markers of cardiotoxicity in breast cancer patients post chemotherapy and the Piccolo-Gavers Translational Research Grant Award for evaluating markers of doxorubicin-induced cardiotoxicity. Okwuosa has also published many peer-reviewed research articles, review articles and editorials in the field of cardio-oncology, including in the Journal of the American College of Cardiology and JAMA. Dr. Okwuosa has spearheaded a number of successful cardio-oncology initiatives at Rush and regionally including the biennial Midwest regional Cardio-Oncology symposium geared toward educating general practitioners involved in the cardiac care of cancer; the triannual Chicago City-wide Cardio-oncology Rounds (CCCR) involving all the major eight Chicago academic institutions; and the biannual Cardio-Oncology patient education seminar series aimed at increasing awareness of and proactiveness in cardiovascular diseases in cancer survivors. She was invited to sit on the Metro Chicago Board for the American Heart Association and is the recipient of numerous awards including Teacher of Year Award for Internal Medicine Residents 2020. She sits on national cardio-oncology committees and writing groups with the American College of Cardiology and the American Heart Association (AHA); is the Vice Chair of the Cardio-Oncology subcommittee for the AHA; and is regionally, nationally and internationally recognized as an expert in cardio-oncology.

Ana Barac, MD PhD is an Associate Professor of Medicine and Oncology at Georgetown University and the director of the MedStar Heart and Vascular Institute's Cardio-Oncology program. She specializes in advanced cardiovascular imaging and cardiovascular care of oncology patients. Dr Barac serves an Associate Editor of JACC Cardio-Oncology and a co-director of the ACC Live Course on Advancing CV Care of Oncology patient. She was the founding Chair of the American College of Cardiology (ACC) Cardio-Oncology Council.

Ashutosh Wechalekar is Professor of Medicine and Haematology at University College London and Honorary Consultant Haematologist at University College London Hospital/Royal Free Hospital, London, UK. His clinical and research is focused on amyloidosis with a particular interest in cardiac amyloidosis. He leads the AL program for UK. His is the director of the Jack O’Neil Amyloidosis laboratory which is focused on amyloid typing and genomics. He leads UK’s first dedicated amyloidosis treatment clinic at University College London Hospitals and is leading development of a UK National Amyloidosis Treatment Network. He leads AL amyloidosis treatment and research in the UK. His research interests including the development of better risk stratification of the disease, reducing early cardiac mortality in AL, imaging, clonal biology and new treatment strategies in AL amyloidosis. He leads on several national and international clinical trials in AL amyloidosis and myeloma at UCL and has published extensively in the respective areas.

Dr Dang is a board-certified medical oncologist and works as part of a multidisciplinary team to care for patients with breast cancer. In her clinical research, she focuses on developing more-effective and less-toxic treatment strategies for women with this disease. Her particular interest is in evaluating combination therapies that include anti-HER2 drugs with chemotherapy in the treatment of patients with early-stage and metastatic HER2-positive breast cancer.

Dr. Hansie Mathelier is Clinical Assistant Professor of Medicine at the University of Pennsylvania. She completed fellowships in Cardiology and Advanced Heart Failure and Transplantation at the University of Pennsylvania. Her clinical areas of expertise include heart failure management, cardio-oncology, cardiac amyloidosis, and mechanical circulatory support. Her clinical interest in cardiology, particularly heart failure, was derived from her time at MIT where she studied chemical engineering. During her medical school and residency training at Johns Hopkins, she was able to integrate engineering and medicine. Her curiosity in cardio-oncologist - started with her interest in cardiac amyloidosis. She has had the privilege to be part of a Center of Excellence for Amyloidosis involving a multidisclipinary approach to the diagnosis and management of this complex disease. She has served as a sub-PI on multiple clinical trials focusing on both amyloidosis and ventricular assist device. She currently serves on the Heart Failure Disease Quality and Cardio-Oncology team for the University of Pennsylvania Health System given her interest in effective treatment of heart failure patients. Her clinical interest is the intersection between cardio-oncology and advanced heart failure.

Dr. Jennifer Ligibel is an Associate Professor at Harvard Medical School and the Director of the Leonard P. Zakim Center for Integrative Therapies and Healthy Living, as well as the Director of the Center for Faculty Well-Being at the Dana-Farber Cancer Institute. Dr. Ligibel’s research focuses on the impact of energy balance factors, such as physical activity and body weight, upon cancer risk and outcomes. She has evaluated the impact of exercise and weight loss interventions on endpoints such as biomarkers associated with cancer risk and outcomes, fitness, body composition, and quality of life in cancer patients and survivors. Dr. Ligibel is currently leading the Breast Cancer Weight Loss (BWEL) Trial, an NCI-funded Phase III clinical trial that is testing the impact of a weight loss intervention upon the risk of disease recurrence in more than 3100 overweight and obese women with early-stage breast cancer. Dr. Ligibel is also a scientific advisory board member and principal faculty for an R-25 funded workshop focused on training junior investigators interested in cancer energetics. Through this role and other research projects, Dr. Ligibel has had the privilege of working with many early-career faculty interested in the role of lifestyle factors in cancer prevention and control. Finally, Dr. Ligibel is a Fellow of the American Society of Clinical Oncology, the immediate past-chair of the ASCO Cancer Prevention Committee, and the Chair of the ASCO Subcommittee on Energy Balance, which strives to raise awareness in the oncology community of the role that obesity and related factors play in influencing cancer risk and outcomes.

Dr. Kasey Leger is a pediatric oncologist at Seattle Children’s Hospital with expertise in the areas of hematologic malignancies and cancer therapy associated cardiotoxicity. Dr. Leger is a Scholar in Clinical Research of the Leukemia & Lymphoma Society. She leads the Children’s Oncology Group (COG) Myeloid Cardiotoxicity Working Group and the cardiac correlative studies embedded in the ongoing COG phase III randomized trial of CPX-351 in children with de novo acute myeloid leukemia (AML). This study aims to evaluate strategies of primary cardioprotection and inform the utility of sensitive echocardiographic measures of myocardial function and cardiac biomarkers in predicting global cardiac dysfunction. Additionally, Dr. Leger is the principal investigator of the Seattle Children’s Cardiotoxicity Cohort Study assessing novel blood and imaging based markers of cardiotoxicity. Dr. Leger’s overarching research goals are to reduce the toxicity of cancer therapy through primary cardioprotective interventions and identify validated risk predictors to guide secondary/ tertiary cardioprotection and ultimately contribute to long-term leukemia cure without the burden of life-threatening heart disease during survivorship.

Dr. Kerry Reynolds is an oncologist at the Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard Medical School. She currently serves as the Director of the Severe Immunotherapy Complications (SIC) Service and the Clinical Director for Inpatient Cancer Services at Mass General Cancer Center. She joined the Harvard Medical School faculty in 2014, after completing her residency and chief residency at Massachusetts General and fellowship training in Oncology at Dana-Farber/Partners Cancer Care. The SIC Service is the first program of its kind in the country. Every hospitalized patient at Mass General Cancer Center who has received immunotherapy and is suspected to be experiencing an immune-related adverse event (irAE) is seen by one of the Service’s dedicated oncologists, resulting in unparalleled care for this type of toxicity. Under the leadership of Dr. Reynolds, the SIC Service now provides care to a significant number of patients every year and has grown to comprise more than 50 clinicians and researchers across 19 different areas of the hospital, including subspecialists from oncology, cardiology, dermatology, gastroenterology, and many more relevant disciplines. In addition to providing clinical care, supervising and educating trainees, and participating in administrative affairs, Dr. Reynolds leverages the work of the SIC Service to conduct research on the severe toxicities associated with immunotherapy. Her ultimate goal is to improve the lives of patients undergoing immunotherapy by uncovering irAE predictors and biomarkers, characterizing the clinical presentations of irAEs, developing best practices for managing irAEs, and elucidating the mechanisms that drive irAEs in order to develop novel therapies. To pursue this goal, she is working with Dr. Alexandra-Chloe Villani to systematically collect blood and tissue samples from patients with irAEs and analyze them using cutting-edge technologies. Dr. Reynolds has also authored numerous peer-reviewed publications and several book chapters, and she was lead editor of Facing Immunotherapy: A Guide for Patients and Their Families.

Kevin Oeffinger, MD, is a family physician, Professor in the Department of Medicine, and a member of the Duke Cancer Institute (DCI). He is founding Director of the DCI Center for Onco-Primary Care, and Director of the DCI Supportive Care and Survivorship Center. He has a long-standing track record of NIH-supported research in cancer screening and survivorship and has served in a leadership capacity in various cancer-focused and primary care-focused national committees and organizations, including the American Society of Clinical Oncology, the American Cancer Society, and the American Academy of Family Physicians. He is currently an Associate Editor for the Journal of the National Cancer Institute. The three-fold mission of the DCI Center for Onco-Primary Care are are to: (1) deliver evidence-based, patient-centered, personalized health care across the cancer continuum by enhancing the interface between cancer specialists and primary care clinicians; (2) conduct innovative research with cutting-edge technology that can be translated to the community setting; and (3) train and educate the next generation of clinicians and researchers to extend this mission. Dr. Oeffinger's clinical expertise is managing survivors of pediatric and young adult cancer.

Dr. Jacobs is the founding Director of the Cancer Survivorship Program at Penn Medicine’s Abramson Cancer Center, the first adult cancer survivorship program in the US, established in 2001. She is a clinician and researcher, providing follow-up care to numerous populations of cancer survivors including testicular and survivors of childhood and young adult cancers. The Penn Cancer Survivorship Program is a national and internationally renowned clinical, research, and education focused multidisciplinary initiative, and Dr. Jacobs has led the effort to develop models of care, research initiatives, and to identify the education needed to prepare providers to care for cancer survivors. Her multidisciplinary research agenda primarily examines the long-term and late effects of cancer treatment experienced by survivors resulting from their diagnosis with particular emphasis on cardiovascular, endocrine, quality of life, and health behavior modification.

Pediatric Cardiologist and Echocardiographer Member, IC-OS Pediatric Cardio-Oncology Committee Coordinator, Pediatric Cardio-Oncology Committee, Brazilian Society of Pediatric Oncology Coordinator, Pediatric Cardio-Oncology Committee, Brazilian Society of Cardiology

Dr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology at the Perelman School of Medicine at the University of Pennsylvania and serves as the medical director of the Penn Medicine Cardio-Oncology program. He earned his B.S at Yale University and his MD degree at the Johns Hopkins University School of Medicine. Dr. Fradley completed his residency in internal medicine through the Osler Medical Residency Program at the Johns Hopkins Hospital. He then went on to complete fellowships in both cardiology and electrophysiology at Massachusetts General Hospital. As a trained electrophysioloigst, Dr. Fradley has particular interest in the diagnosis and management of arrhythmic complications associated with traditional and novel cancer therapies. He is a member of the American College of Cardiology Electrophysiology Leadership Council and the IC-OS Board of Directors.

Sebastian Szmit graduated from the Military Medical Academy in Poland. He began cardio-oncology activities in 2006 working for the Department of Oncology of the Military Institute of Medicine. He was appointed the executive editor of the Task Force of National Consultants in Cardiology and Clinical Oncology, and developed the first two Polish Recommendations on cardiovascular safety of patients with breast cancer (published in 2010) and lung cancer (published in 2012). Since 2012 he has served as the cardio-oncology consultant at the Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, at the Centre of Postgraduate Medical Education in Poland. In 2015 he was appointed as the scientific director of the "Oncology in Cardiology" training program. He is the cardio-oncology research coordinator for the Polish Lymphoma Research Group and the Polish National Oncology Network. He co-authored two educational books: "Hypertension-oncology: arterial hypertension in cancer disease" and "Cardiovascular complications in cancer patients" published in 2018 under auspices of the Polish Society of Clinical Oncology, Since 2019 he has been a Member of the Executive Committee of the Global Cardio-Oncology Summit (GCOS) and a Member of the Education & Training Advisory Committee of the International Cardio-Oncology Society (ICOS) and in 2020 he was awarded an Honorary Member of the Cardio-Oncology Society of Southern Africa (COSOSA), a Fellow of the International Cardio-Oncology Society (FICOS), and a Board Member of the European Society of Cardiology (ESC) Council of Cardio-Oncology. On May 26th 2021, Dr. Szmit was asked by the Scientific Council of the Centre of Postgraduate Medical Education to lead the newly created "Cardiooncology Department and Echocardiography Laboratory" based at the European Health Centre in Otwock (oncology center) and the Institute of Hematology and Transfusion Medicine in Warsaw.

Stephen J. Schuster, MD is the Robert and Margarita Louis-Dreyfus Professor of CLL and Lymphoma and a professor of medicine at the University of Pennsylvania. He is also the Director of the Lymphoma Program and Director of Lymphoma Translational Research at the Abramson Cancer Center. After graduating AOA from Jefferson Medical College and completing his residency at Pennsylvania Hospital, Dr. Schuster completed clinical and research fellowships at the Cardeza Foundation for Hematologic Research. In 1989, he became a member of the Cardeza Foundation at Jefferson Medical College. Dr. Schuster joined the University of Pennsylvania in 1998. Since then, his research has focused on the development and application of novel immunotherapies for B-cell lymphomas and CLL, including autologous tumor-derived vaccines, autologous costimulated T-cells, radioimmunotherapy, monoclonal antibody therapy, bispecific antibody therapy, and adoptive immunotherapy using chimeric antigen receptor modified T cells (CAR-T cells) He has over 300 publications and has received numerous awards for outstanding teaching and research.

Dr. Gilchrist is an expert in cardiovascular prevention with a special focus on patients with cancer. She has a VO2 testing lab within her clinical practice, providing objective cardiorespiratory fitness assessment and personalized exercise prescriptions for patients. This is the first cardiovascular prevention program in the U.S. focused exclusively on improving fitness and mitigating existing cardiovascular risk factors in patients treated for cancer. Dr. Gilchrist’s clinical research program focuses on epidemiological studies relating fitness to cancer outcomes and clinical studies to assess the optimal intensity, duration, and timing of exercise training in the chemoprevention setting as well as during and after cancer treatment.

Dr. Neilan received his M.D. from University College Dublin and MPH from Harvard School of Public Health. He completed internal medicine residency and cardiology training at the Mater Misericordiae Hospital in Dublin and again at Massachusetts General Hospital. He has also completed extensive training in echocardiography at Massachusetts General Hospital and cardiac magnetic resonance at the Brigham and Women's Hospital. Dr. Neilan is an Associate Professor of Medicine at Harvard Medical School, the Director of the Cardio-Oncology Program and the Co-Director of the Cardiac MR PET CT Program. Dr. Neilan has had a long-standing clinical and research interest in the cardiovascular care of patients with cancer. Cardiovascular disease is a leading cause of death and disability among cancer survivors and cardiovascular care for patients with cancer requires a tailored approach that is unique for each patient. He is specifically interested in how we can improve on the methods for detection of the cardiac toxicity after chemotherapy and radiotherapy and to use that information to determine how we care for patients.

Dr. Vivek Narayan, MD MSCE is an Assistant Professor of Medicine in the Division of Medical Oncology at the University of Pennsylvania Abramson Cancer Center. His clinical and research interests are specifically focused on the care of patients with advanced prostate cancer and kidney cancer. He serves as principal investigator on several therapeutic oncology clinical trials, including multiple investigator-initiated studies. He additionally seeks to improve survivorship care for patients with cancer, including the evaluation and management of cardiac toxicities of cancer therapies for prostate and kidney cancers. Dr Narayan’s early career achievements have been nationally recognized, with selection as the 2018 AUA Urology Care Foundation Outstanding Graduate Scholar Award, as well as a recipient of the 2018 Prostate Cancer Foundation Young Investigator Award. He has received research funding from the American Cancer Society, American Urological Association, and the Prostate Cancer Foundation.

I am a tenured Associate Professor of Medicine and Epidemiology and physician scientist at the University of Pennsylvania. My fundamental goals are to gain insight into the underlying mechanisms and predictors of cancer therapy cardiotoxicity, and to translate this understanding to the clinical care of patients. I lead a highly active NIH-funded translational research program in cardio-oncology and am the PI of multiple investigator-initiated cohort studies and clinical trials focused on the study of the cardiotoxic effects of doxorubicin, trastuzumab, anti-angiogenic tyrosine kinase inhibitors, androgen deprivation therapy, and radiation therapy in breast, renal cell, prostate and lung cancers, and lymphoma patients. My programmatic objectives are to understand how we can improve cardiovascular outcomes in cancer patients by determining individual patient risk, through detailed phenotyping of clinical characteristics, the social determinants of health, biologic markers, and echocardiography-derived measures of myocardial mechanics and function. I also serve as the Director for the Penn Center for Quantitative Echocardiography and the Founding Director of the Penn Cardio-Oncology Translational Center of Excellence and have built a strong, multi-disciplinary collaborative network comprised of highly successful basic, translational, and clinical researchers. I am an invited member of many cardio-oncology expert consensus and research groups within the NIH, FDA, American Society of Clinical Oncology, American College of Cardiology, American Heart Association, and European Society of Cardiology focused on advancing our understanding of cardiovascular disease in the growing cancer population. I am the Inaugural Editor-in-Chief of JACC: CardioOncology, and successfully launched this important scientific and clinical resource. I have specialized expertise in cardio-oncology, epidemiology, the study of biomarkers, and imaging tools to understand cardiac remodeling, function, and risk prediction.

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Dr. Alexander Lyon is a Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. His clinical interests are in the field of heart failure, cardio-oncology including chemotherapy cardiomyopathy and the cardiovascular complications of modern cancer therapies, Takotsubo syndrome and the effects of major stresses of the heart, and the development of novel therapeutics including gene therapy for chronic heart failure. Alex has published over 180 scientific papers in peer-reviewed journals, several book chapters in cardiology textbooks including the chapter on cardiotoxicity of tyrosine kinase inhibitors in the latest edition of the ESC Textbook of Cardiology. He is a deputy editor of the European Heart Journal, an associate editor of the European Journal of Heart Failure, international advisor to the journal JACC Cardio-Oncology and his H-index is 44. Alex is the clinical lead for the Cardio-Oncology service at the Royal Brompton Hospital since 2011, specialising in surveillance and cardioprotection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment. Alex is the current president of the British Cardio-Oncology Society, recently appointed a board member of International Cardio-Oncology Society (ICOS - 2021), chair-elect European Society of Cardiology (ESC) Council of Cardio-Oncology (2020-2022) and he is the cardiology advisor to the charity Macmillan Cancer. Alex is a co-investigator of the first Leducq Cardio-Oncology Transatlantic Research Network funded from 2020-2025 ($6M). Alex is a co-chair of the first ESC Cardio-Oncology Guideline which will be published in 2022. Alex completed a full 4 year term on the board of the Heart Failure Association of the ESC (2016-2020), and he initiated and was the chair of the Heart Failure Association Cardio-Oncology Study Group. He is a co-author of the ESC Position Statement on Cardio-Oncology, the ESC Cardio-Oncology Council article on the setting up and delivery of Cardio-Oncology services and the 2020 ESMO guidelines on the management of cardiac diseases in cancer patients. He is a member of the International Cardio-Oncology Society and Alex was co-chair of the 2017 Global Cardio-Oncology Summit which hosted 325 specialists from 33 countries at the Royal College of Physicians in London in September 2017.

Dr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the University of Minnesota. She is the section head of Medical Oncology within this division and is Director of Cancer Survivorship Services and Translational Research within the Masonic Cancer Center. She is an active medical oncologist with a special interest in the late effects of cancer therapy, particularly in the area of cardio-oncology. Her research focuses on designing and implementing strategies to help prevent the long term complications of treatments in our cancer survivors, particularly in the areas of cardiovascular health. She is the Chair for the American Society of Clinical Oncology’s Cancer Survivorship Committee, a member of the Executive Board for the Global Cardiooncology Society, associate editor for JACC Cardio-oncology, section editor for Hem/Onc Today on Survivorship and an active member of the ALLIANCE for Cancer Clinical Trials.

Dra. Macedo is an assistant physician and coordinator of the cardio-oncology clinic at Santa Casa de São Paulo School of Medicine, São Paulo, Brazil. She is also chair of the cardio-oncology department of Rede D’Or São Luiz health network and researcher/faculty at BCRI (Brazilian Clinical Research Institute). Her clinical background includes MD and Master in Health Sciences at the University of Minas Gerais, Brazil. Currently, she is finishing the Ph.D. program at the Federal University of São Paulo, Brazil. She is an active member of scientific organizations serving now as Vice President of the cardio-oncology chapter of the Brazilian Society of Cardiology, Director of the Brazilian Society of Thrombosis and Hemostasis, and Member of the Council of Cardio-Oncology of the Interamerican Society of Cardiology. In 2019 she was certified to be a fellow of the European Society of Cardiology. She is currently developing consensus documents in cardio-oncology and the definition of core educational topics to provide structured training in cardio-oncology.

Dr. Bénédicte Lefebvre is an Assistant Professor of Clinical Medicine at the University of Pennsylvania. Dr. Lefebvre earned her medical degree from McGill University, Montreal, Canada where she also completed her training in internal medicine and general adult cardiology. She then completed a two-year fellowship in advanced cardiac imaging at the University of Pennsylvania specializing in echocardiography, structural echocardiography and cardiac magnetic resonance. Afterwards, she underwent a cardio-oncology fellowship at the University of Pennsylvania. Dr. Lefebvre’s research focuses on the cardiovascular effects of CAR T cells and the use of cardiac imaging and biomarkers to detect cardiotoxicity.

Charles Porter MD established the Cardio-oncology program for the University of Kansas Cancer at the University of Kansas Medical Center in 2007. He was designated as the inaugural American Vice-President of IC-OS in 2009. He has overseen the growth of the KUMC cardio-oncology program and continues to expand its collaboration with a broad array of oncologists in patient care and research. Research includes studies in BMT outcomes, 5FU cardiotoxicity and breast cancer treatment cardiotoxicity. He is associate editor for Cardiooncology, an editorial consultant for JACC Cardiooncology, and is a member of the IC-OS Science and Research Committee. He has multiple publications and presentations in the field.

Charlotte Manisty is Associate Professor of at University College London and set up and leads the largest cardio-oncology service in the UK at Barts Hospital, London. She and also has expertise in heart failure and cardiac imaging, and leads a research group whose current research interests include optimising imaging using computational techniques for identifying patients at risk of developing cardiotoxicity, and understanding the vascular toxicity of chemotherapeutic agents. She chairs the SCMR Cardio-oncology group, and is Research Lead for British Cardio-oncology Society. She is regularly invited to speak both Nationally and at International conferences on Cardio-oncology and Imaging, and chairs the UK Multi-Societal Working Group on MRI in patients with cardiac devices. She receives funding for her work from BHF and NHLI, and has published over 100 papers and book chapters, alongside supervising PhD students and teaching.

Dr Addison is a clincal inviestigator and practicing cardiologist with unique expertise in cardiovascular imaging and cardio-oncology. He completed his Medicine and General Cardiology training at Baylor College of Medicine in 2015. He joined The Ohio State University following the completion of a NIH T-32 advanced cardiovascular imaging fellowship at Massachusetts General Hospital in Boston, MA, where he focused in cardio-oncology. He currently serves as co-director of the Cardio-Oncology Program at the Ohio State Comprehensive Cancer Center, where he employs advanced imaging techniques to understand the pathophysiologic mechanisms and potential targets of interventions for cardiovascular disease(s) among cancer survivors at risk for cardiovascular events. To date, his efforts focus on the interplay of cancer-treating radiotherapy and cardiovascular events, the early detection of anthracycline-associated cardiotoxicity, and the early detection and mechanisms of cancer targeted and immunotherapy-associated cardiovascular diseases, for which I am supported by the NCI, AHA, and RWJ.”

Dr. Daniela Cardinale is specialized in Cardiology. She holds a PhD in Cardiovascular Physiopathology in 2009. She is currently Director of the Cardioncology Unit of the European Institute of Oncology in Milan. Her professional experience and investigational interests focus on prevention, early detection, monitoring and treatment of cardiotoxicity; screening of cardiotoxicity in patients with cardiac disease; malignant pericardial effusion evaluation and intrapericardial treatment.

Husam Abdel-Qadir is a cardiologist at Women’s College Hospital and the Peter Munk Cardiac Centre, and a scientist at Women’s College Research Institute, the Ted Rogers Centre for Heart Research, and ICES. He graduated from the University of Toronto’s medical school with the Silver Medal and completed residencies in Internal Medicine and Cardiology at the University of Toronto. During his training, Dr. Abdel-Qadir became interested in optimizing the cardiovascular health of people who are less likely to be represented in clinical trials. This motivated him to pursue a PhD in Clinical Epidemiology and Health Care Research at the Institute for Health Policy, Management, and Evaluation. His PhD thesis focused on the cardiovascular health of women with breast cancer, and this continues to be a focus of his research program. His clinical and research expertise also extends to the cardiovascular health of people with other cancers. He is also developing a research program on the management and outcomes of people with atrial fibrillation. His research is supported by an early career Chair in Heart and Brain Health and the 2020 National New Investigator Award from the Heart and Stroke Foundation of Canada. He has also received the Canadian cardiovascular Society Atrial Fibrillation Research Award, European Society of Cardiology Young Investigator Award, the inaugural Young Investigator Competition at the 2017 Global Cardio-Oncology Summit, and the 2018 Polanyi prize in Medicine/ Physiology. Dr. Abdel-Qadir also sits on the board of the Black Physicians’ Association of Ontario and serves as its Director of Continuing Professional Development.

He is a cardiologist and myocyte biologist. his clinical focus is cardio-oncology (the cardiovascular care of cancer patients and cancer survivors). His basic and translational NIH-funded laboratory addresses myocardial responses to various stresses including hypoxia, aging and toxins. Over the last several years, given his clinical interest in cardio-oncology, his laboratory focus has been in delineating the mechanistic underpinnings of cardiovascular toxicities from novel targeted cancer therapies. He believes because of the targeted nature of the toxicities, cardio-oncology can provide insights into novel signalling pathways that are relevant in human cardiovascular biology and pathology. At Vanderbilt, He is an Associate Professor of Medicine, Director of Cardio-Oncology and Co-director of Vanderbilt Program for Optimizing Immuno-oNcology Therapy (V-POINT). He works closely with cardiologists and oncologists, basic, translational researchers and clinicians locally, nationally and internationally. He has also started several collaborations with industry and regulatory bodies (including the US FDA). He was recently named the first chair of the American Heart Association (AHA) cardio-oncology subcommittee. At Vanderbilt, he has established a Graduate Medical Education (GME) approved fellowship training the next generation of physician-scientists in the field of cardio-oncology. He is an elected member of American Society of Clinical Investigation (ASCI).

Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.

Joshua Mitchell, MD, MSCI is an Assistant Professor of Medicine and Director of the Cardio-Oncology Fellowship at the Cardio-Oncology Center of Excellence, Washington University School of Medicine in St. Louis. Prior to coming to Washington University in 2015, he served 11 years in the US Army, deploying with the 82nd Airborne Division and the 75th Ranger Regiment, earning two Bronze Start Medals, and reaching the rank of Major. He is currently a member of the ICOS Scientific Committee and recently helped lead the 2021 ICOS expert consensus statement for cardiovascular disease screening in radiation survivors. He also serves on the JACC:Cardio-Oncology editorial board and is the Co-Chair for the ACC Cardio-Oncology working group. His clinical and research interests include better characterizing and understanding cardiovascular disease associated with cancer treatment, and the diagnosis of management of cardiac amyloidosis. His research has also focused on the use of coronary artery calcium to improve risk prediction and help target preventive therapy. As the Cardio-Oncology fellowship director at Washington University in St. Louis, he has directed the training and development for full year fellows, rotations for internal cardiology fellows, and rotations for both external cardiology fellows and for board certified cardiologists looking for additional training in Cardio-Oncology to improve their practice.

Dr. Lova Sun is an Assistant Professor in the Division of Hematology/Oncology at the University of Pennsylvania. Her clinical focus is head/neck and lung cancers, and her research interests include improving survivorship and cardiovascular outcomes in patients with cancer.

Mary Branch is an administrator at Wake Forest Baptist Medical Center, Winston Salem, USA.

Dr Raul Cordoba is Head of the Lymphoma Unit at the Fundacion Jimenez Diaz University Hospital, Madrid, Spain. He obtained his Bachelor of Medicine degree from the Autonomous University of Madrid and went on to specialise in haematology at the University Hospital La Princesa, Madrid. He first started his research in the field of lymphoid neoplasms, achieving his Master’s degree in Molecular Oncology from the Spanish National Cancer Research Centre, Madrid, and his PhD from the Department of Medicine at the Autonomous University of Madrid. He is also the Principal Investigator for the Haematology Programme of START Madrid-FJD, a unit dedicated exclusively to Phase I trials in oncology. He serves as the vice-president of the Spanish Group of Geriatric Hematology of the Spanish Society of Hematology and Hemotherapy (SEHH) since 2012. He is the chair of the EHA-Scientific Working Group "Aging and Hematology"" of the European Hematology Association (EHA) since 2019. Since 2014, Dr Cordoba is the National Representative of the International Society of Geriatric Oncology (SIOG) in Spain and member of the Board of Directors since 2020. He is member of the American Society of Hematology (ASH) and American Society of Clinical Oncology (ASCO) where he has given lectures in scientific symposia and educational programs with the topic of geriatric hematology.

Dr Ganatra serves as a Director of the Cardio-Oncology Program and Co-Director of the Cardiac MRI Program for Lahey Hospital and Medical Center, Beth Israel Lahey Health in Boston. His primary research interest is outcomes research in cardio-oncology. He serves on the Research and Scientific Committee of the International Cardio-Oncology Society (ICOS), the American College of Cardiology Cardio-Oncology leadership council, and on the editorial board of JACC Cardio-Oncology.

I am a third-year internal medicine resident at Mayo Clinic, Rochester and a rising Oncology fellow at Stanford University. I graduated with degrees in Molecular Biology and Human Development with a minor in Humanities from University of California, San Diego and completed medical school at the Keck School of Medicine at the University of Southern California. Cardio-oncology is one of my primary research interests as preserving cardiac health is a critical component of comprehensive oncologic care. More specifically, I am interested in understanding specific patient factors that put certain patients at higher risk for cardiotoxicity and the utilization of biomarkers for the early detection of impaired cardiac health.

Dr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed her residency training in Internal Medicine and Medical Oncology at the Ottawa Hospital, University of Ottawa, Ontario, Canada. She subsequently completed a post graduate research fellowship in clinical trials at the Canadian Cancer Trials Group (CCTG) in Kingston, Ontario, and was appointed as a staff medical oncologist at the Northwestern Ontario Cancer Center in Thunder Bay, Ontario. In 2001, Dr. Dent returned to Ottawa, where she specialized in the treatment of breast cancer. In 2008, Dr. Dent, working with her cardiology colleagues, established a multidisciplinary cardio-oncology clinic in Ottawa; the first of its kind in Canada. In 2011, she founded the Canadian Cardiac Oncology Network (CONN), a not-for-profit organization devoted to optimization of cancer care for patients without compromising cardiovascular health. In 2015, Dr. Dent launched the Global Cardio-Oncology Summit (GCOS), an annual meeting which now attracts oncologists, cardiologists, and allied health care providers from more than 23 countries. Dr. Dent is recognized as a global leader in cardio-oncology. She has travelled extensively around the world sharing her knowledge and expertise on the potential impact of cancer treatment on cardiovascular health. She has published extensively in the area and has co-authored a number of position statements and clinical practice guidelines. Dr. Dent currently serves as an Executive Officer of the International Cardio-Oncology society (ICOS), an organization dedicated to bringing cardiologists, oncologists, and allied health care providers together, to improve the clinical care of patients and save lives. In September 2018, Dr. Dent accepted a staff position in medical oncology at Duke University, where she will continue her efforts in promoting clinical care, education and research in cardio-oncology.

Dr Arjun K Ghosh MBBS, MSc, PhD, FHEA, FACC, FESC, FRCP, FICOS is a Consultant Cardiologist at Barts Heart Centre (BHC), St. Bartholomew’s Hospital, London and at University College London Hospital (UCLH). He is the first cardiologist in the UK to be appointed specifically in cardio-oncology and helped establish Cardio-Oncology services at both these hospitals which are now amongst the biggest services worldwide. Arjun leads the cardio-oncology service at UCLH. Arjun is also actively involved in developing cardio-oncology curricula and guidelines and changing practice through the British Society of Echocardiography, British Cardio-Oncology Society and International Cardio-Oncology Society and UK Specialist Advisory Committee (SAC). He was joint first author of the first British cardio-oncology guidelines published earlier this year. He runs the UK’s only national Cardio-Oncology Study Day and help organise the only pan-European Cardio-oncology Symposium. Outside of the interesting world of cardiology’s newest subspecialty Arjun is involved in cardiac MRI (CMR) and cardio-oncology echocardiography and has several national and international leadership and management positions at the British Cardiovascular Society, the Royal Society of Medicine, the British Cardio-Oncology Society and the International Cardio-Oncology Society. He is the co-host of the ICOS podcast and has recently been appointed to the ACC Cardio-Oncology Leadership Council. You can find him on Twitter @arjunkg.

Bio: Dr. Guha is an Assistant Professor of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, and a consultant cardiologist in the Harrington Heart and Vascular Institute. He is an expert in cardiovascular epidemiology pertaining to cardio-oncology. Additionally, he is a faculty member of the Harrington Heart and Vascular Insitute's cardio-oncology program. Finally, he is a member of the JACC: Cardio-oncology and ICOS SoMe working groups.

Dr Ruddy is a breast medical oncologist at Mayo Clinic Rochester who co-leads the Symptom Control/Survivorship Cross-Disciplinary Group and the Population Sciences Program for Mayo Clinic Cancer Center across all Mayo Clinic sites. Cardiotoxicity is one of her primary research interests, and she is co-PI of an R01-funded clinical trial assessing carvedilol as a cardioprotectant during Her2-directed therapy for breast cancer. she is a member of the NCCN Survivorship Guidelines Committee, a vice chair of the Symptom Intervention Committee in the Alliance for Clinical Trials in Oncology, and an Associate Editor at JNCI and at JACC Cardio-Oncology.

Richard Cheng, MD, MSc is a HF cardiologist and cardio-oncologist with a focus on education, risk stratification, imaging, and treatment strategies for HF, cardiomyopathies, cardiac amyloidosis and cancer therapy-associated cardiac dysfunction. His recent research interests include the prevention of cardiovascular disease, epidemiology, and long-term cardiovascular complications of cancer treatment in breast cancer survivors and stem cell transplant recipients. He also has ongoing studies focused on risk stratification, multimodality imaging and outcomes in cardiac amyloidosis, cardiomyopathies, heart transplantation and LVAD recipients. He serves on the editorial boards of JACC, JACC: Cardio-Oncology, ACC.org, Heart, and the Journal of Heart and Lung Transplantation.

Dr. Rupal O'Quinn is an Assistant Professor of Clinical Medicine at the University of Pennsylvania, and the Director of Cardio-Oncology at Penn Presbyterian Medical Center. Dr. O’Quinn joined the faculty in 2015, and specializes in the field of cardio-oncology and multi-modality cardiovascular imaging that includes echocardiography and cardiac magnetic resonance. She is currently on the Research and Scientific Advisory Committee of the International Cardio-Oncology Society (ICOS), as well as a member of the Training in Cardio-Oncology and Cardio-Oncology Advocacy workgroups within the American College of Cardiology. Dr. O'Quinn completed a fellowship at the Hospital of the University of Pennsylvania in 2015, where she focused on Cardio-Oncology. Prior to that, Dr. O'Quinn completed a General Cardiology Fellowship at Beth Israel Deaconess Medical Center - Harvard University Medical School in Boston, Massachusetts with a focus in cardiovascular imaging. She is currently pursuing a Master of Healthcare Innovation at the University of Pennsylvania, with expected completion in May, 2023. Dr. O'Quinn completed her residency and chief medical residency at the University of Michigan Health Systems in Ann Arbor, Michigan. She attended medical school at the Rutgers Medical School/University of Medicine and Dentistry of New Jersey, and college at Boston University where she graduated Summa Cum Laude.

Dr. Arnold is a native New Yorker and studied General and Interventional Cardiology at the Cleveland Clinic Foundation in Cleveland, Ohio, USA. As a cancer survivor herself, she is passionate about Cardio-Oncology and presently is an Associate Professor of Medicine at Florida State University, the Founding Director of the Cardio-Oncology program and Transitional Clinic for childhood cancer survivors at Lee Health in Florida, a Board of Director member and Chair of the Education Committee for ICOS, and the past chair of the Advocacy working group for the Cardio-Oncology section of the American College of Cardiology. She is interested in disparities in healthcare especially as it relates to Cardio-Oncology.

Dr. Anju Nohria is the Director of the Cardio-Oncology Program at Dana-Farber/Brigham and Women’s Cancer Center and a cardiovascular specialist in heart failure and transplantation at Brigham and Women’s Hospital (BWH). In addition, she is an Assistant Professor of Medicine at Harvard Medical School (HMS). Dr. Nohria received her medical degree from HMS. She completed an internal medicine residency and was a chief resident at Yale-New Haven Hospital. She then completed both a cardiovascular medicine fellowship and a heart failure and transplantation fellowship at BWH. She is board certified in cardiovascular disease and heart failure and transplantation. Dr. Nohria’s clinical interests include cardio-oncology and heart failure and transplantation. The author of approximately 100 peer-reviewed publications, she currently researches how to evaluate, prevent and treat cardiovascular complications that can arise as a result of cancer therapy.

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Lauren A. Baldassarre, MD is Associate Professor of Cardiovascular Medicine and Radiology & Biomedical Imaging at Yale School of Medicine in New Haven, CT. She is the Director of the Yale Smilow Cancer Center Cardio-Oncology Program and the Cardiology Director of Cardiac MR/CT for Yale New Haven Hospital. She is also the Program Director for the newly established Yale Cardio-Oncology Advanced Fellowship Program. Dr. Baldassarre is a member of the American College of Cardiology Cardio-Oncology Section Leadership Council and is the Chair of the International Cardio-Oncology Society Imaging Work Group. She is the Chair of the Society for Cardiovascular Magnetic Resonance Cardio-Oncology Special Interest Group and is a member of the Society of Cardiovascular Computed Tomography Cardio-Oncology Writing Group. Her clinical and research interests include the use of advanced multimodality cardiac imaging for the detection, management, and prevention of cardiotoxicity from cancer therapeutics.

Dr. Roohi Ismail-Khan is a medical oncologist and provides care for cancer patients in the Cardio-Oncology and Survivorship Programs. She has an interest in Women’s Health and has served more than 10 years taking care of Breast Cancer patients and has now joined the gynecologic oncology program at Moffitt Cancer Center. Recently, she has concentrated her clinical efforts to help patients with cancer who also have high risk cardiovascular disease. She works closely with Cardiology in helping patients balance the treatment for their cancer and their co-existing CV disease. She serves as the co-director of the new Cardio-Oncology Program. She completed her Internal Medicine Residency at the University of South Florida and served as chief resident in her final year. She completed her Medical Oncology Fellowship at the H. Lee Moffitt Cancer Center and completed her MS in Clinical Research during her fellowship. Her clinical focus and research is focused upon identifying high risk patient cohorts and minimizing cardiovascular side effects in patients receiving cardio-toxic therapy. Dr. Ismail-Khan is also an active teacher and mentor for USF medical students, Internal Medical residents, and Medical Oncology Fellows.

Dr. Stephen Casselli is an executive director at International Cardio-Oncology Society.

Dr. Vijay Rao is the Director of CardioOncology, Heart Failure, and Anticoagulation at Franciscan Health, Indianapolis, Indiana. He graduated with a dual degree MD and PhD from the Medical University of South Carolina followed by Internal Medicine training at Duke University Medical Center. He then completed Cardiology fellowship at the University of California, San Francisco followed by a dedicated additional year in echocardiography serving as the Chief Fellow. He is the governor-elect for the Indiana Chapter of the American College of Cardiology. Under his leadership, the Franciscan CardioOncology team was awarded an Associate of Community Cancer Centers National Innovator Award in 2020 for “Nurse Navigation as a Model for Developing an CardioOncology Program.” Dr. Rao was also the first author on a recent State of the Art Review published in Journal of American College of Cardiology June 2021 issue titled “Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents.” He also serves as the Chair of the ICOS Center of Excellence Committee and is an active member of the ICOS Education Committee.

Dr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the University of Minnesota. She is the section head of Medical Oncology within this division and is Director of Cancer Survivorship Services and Translational Research within the Masonic Cancer Center. She is an active medical oncologist with a special interest in the late effects of cancer therapy, particularly in the area of cardio-oncology. Her research focuses on designing and implementing strategies to help prevent the long term complications of treatments in our cancer survivors, particularly in the areas of cardiovascular health. She is the Chair for the American Society of Clinical Oncology’s Cancer Survivorship Committee, a member of the Executive Board for the Global Cardiooncology Society, associate editor for JACC Cardio-oncology, section editor for Hem/Onc Today on Survivorship and an active member of the ALLIANCE for Cancer Clinical Trials.

Christine Brezden-Masley, MD PhD FRCPC is a practicing Medical Oncologist and the Director of the Marvelle Koffler Breast Centre at Mount Sinai Hospital as well as the Medical Director of Cancer Program for Sinai Health in Toronto, Canada. She obtained her PhD in Medical Biophysics at the Princess Margaret Hospital in Toronto and her Medical Degree from the University of Toronto. She is currently an Associate Professor at the University of Toronto and senior scientist for the same Clinical Research Group at the Lunenfeld-Tanenbaum Research Institute for Sinai Health System in Toronto, Canada. Dr Brezden-Masley is the founder of the COMET (Community Oncologists of Metropolitan Toronto) Clinical Trials Consortium, a web-based virtual network promoting cancer clinical trials throughout the Toronto region. She treats both breast and gastrointestinal (colorectal and gastric cancers) malignancies, which are her major areas of research interest. Her main area of clinical research is cardiotoxicity from cancer therapy and is currently the President of the Canadian Cardio-Oncology Network. She is also on the Board of Directors of ReThink Breast Cancer, a national advocacy and support network for young women with breast cancer and My Gut Feeling, a stomach cancer support network for patients, survivors, and caregivers.

Dr. Dinesh Thavendiranathan is a cardiologist at the Peter Munk Cardiac Center at the Toronto General Hospital, University of Toronto. He is an Associate Professor of medicine and a Clinician Scientist. Dr. Thavendiranathan’s Clinical work involves cardiac MRI, CT, and echocardiography and Cardio-oncology. He is the Director of the Ted Rogers Program in Cardiotoxicity Prevention. His research focus is in the use of advanced cardiac imaging techniques for detection and management of cardiac toxicity. He holds a Canada Research Chair in Cardio-oncology.

Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.

Dr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology at the Perelman School of Medicine at the University of Pennsylvania and serves as the medical director of the Penn Medicine Cardio-Oncology program. He earned his B.S at Yale University and his MD degree at the Johns Hopkins University School of Medicine. Dr. Fradley completed his residency in internal medicine through the Osler Medical Residency Program at the Johns Hopkins Hospital. He then went on to complete fellowships in both cardiology and electrophysiology at Massachusetts General Hospital. As a trained electrophysioloigst, Dr. Fradley has particular interest in the diagnosis and management of arrhythmic complications associated with traditional and novel cancer therapies. He is a member of the American College of Cardiology Electrophysiology Leadership Council and the IC-OS Board of Directors.

Dr. Dent attended McMaster University Medical School in Hamilton, Ontario, Canada and completed her residency training in Internal Medicine and Medical Oncology at the Ottawa Hospital, University of Ottawa, Ontario, Canada. She subsequently completed a post graduate research fellowship in clinical trials at the Canadian Cancer Trials Group (CCTG) in Kingston, Ontario, and was appointed as a staff medical oncologist at the Northwestern Ontario Cancer Center in Thunder Bay, Ontario. In 2001, Dr. Dent returned to Ottawa, where she specialized in the treatment of breast cancer. In 2008, Dr. Dent, working with her cardiology colleagues, established a multidisciplinary cardio-oncology clinic in Ottawa; the first of its kind in Canada. In 2011, she founded the Canadian Cardiac Oncology Network (CONN), a not-for-profit organization devoted to optimization of cancer care for patients without compromising cardiovascular health. In 2015, Dr. Dent launched the Global Cardio-Oncology Summit (GCOS), an annual meeting which now attracts oncologists, cardiologists, and allied health care providers from more than 23 countries. Dr. Dent is recognized as a global leader in cardio-oncology. She has travelled extensively around the world sharing her knowledge and expertise on the potential impact of cancer treatment on cardiovascular health. She has published extensively in the area and has co-authored a number of position statements and clinical practice guidelines. Dr. Dent currently serves as an Executive Officer of the International Cardio-Oncology society (ICOS), an organization dedicated to bringing cardiologists, oncologists, and allied health care providers together, to improve the clinical care of patients and save lives. In September 2018, Dr. Dent accepted a staff position in medical oncology at Duke University, where she will continue her efforts in promoting clinical care, education and research in cardio-oncology.